Mutation Detection Kits in Genome Editing Market Report 2026

The mutation detection kits in genome editing market size has grown rapidly in recent years. It will grow from $1.14 billion in 2025 to $1.29 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to limited availability of mutation detection kits, reliance on manual and traditional detection techniques, growing genome editing research, increasing demand for precise validation tools, adoption of basic nucleic acid reagents.

The mutation detection kits in genome editing market size is expected to see rapid growth in the next few years. It will grow to $2.1 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to development of advanced crispr-based mutation validation kits, rising investment in next-generation sequencing technologies, expansion of cloud-based bioinformatics solutions, increasing applications in clinical diagnostics and personalized medicine, integration of ai-driven data interpretation tools. Major trends in the forecast period include rising adoption of pcr-based and next-generation sequencing mutation detection kits, increasing use of crispr mutation validation tools in genome editing research, growth in software solutions for genomic data analysis and visualization, expansion of mutation detection applications in drug development and clinical diagnostics, integration of cloud-based bioinformatics platforms for real-time data interpretation.

The rising prevalence of genetic disorders is expected to drive the growth of the mutation detection kits in the genome editing market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, which may be inherited from parents or arise from new mutations. The increasing prevalence of these disorders is fueled by greater awareness and advances in diagnostic technologies, enabling earlier and more accurate detection and consequently higher reported rates. Mutation detection kits in genome editing support the management of genetic disorders by precisely identifying disease-causing gene mutations, facilitating targeted research and the development of tailored therapeutic interventions. For instance, in May 2024, according to the National Health Service, a UK-based government department, approximately 17,000 people in England live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. Therefore, the growing prevalence of genetic disorders is a key driver for the mutation detection kits market.

Major companies operating in the mutation detection kits market are focusing on developing advanced solutions, such as ultrasensitive multiplexed assays, to enhance accuracy, speed, and sensitivity in detecting genetic mutations. Ultrasensitive multiplexed assays are diagnostic tools capable of detecting and quantifying multiple genetic mutations simultaneously at very low levels, enabling faster, more precise, and comprehensive mutation analysis for disease diagnosis and monitoring. For example, in April 2024, Bio-Rad Laboratories Inc., a US-based research company, launched the ddPLEX ESR1 Mutation Detection Kit, an ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection. This kit allows simultaneous identification and quantification of seven ESR1 mutations with an analytical sensitivity as low as 0.01% variant allele fraction, supporting analysis of both plasma and tissue samples. Such innovations highlight the industry’s focus on improving diagnostic precision and enabling more effective disease monitoring and personalized treatment strategies.

In March 2025, ERS Genomics Limited, an Ireland-based biotechnology company, partnered with Jumpcode Genomics Inc. to advance next-generation sequencing (NGS) capabilities. Through this collaboration, Jumpcode Genomics Inc. aims to leverage ERS Genomics’ CRISPR/Cas9 patent portfolio to enhance NGS technologies, achieving higher sensitivity, improved efficiency, and broader applications in areas such as basic research, infectious disease detection, molecular diagnostics, and oncology. Jumpcode Genomics Inc., a US-based life sciences tools company, specializes in providing advanced tools for mutation detection and genome editing.

Major companies operating in the mutation detection kits in genome editing market are F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., QIAGEN N.V., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio Inc., Promega Corporation, Analytik Jena AG, Twist Bioscience Corporation, New England Biolabs Inc., Applied Biological Materials Inc., Synthego Corporation, BioVision Inc., Creative Biogene Corporation.

North America was the largest region in the mutation detection kits in genome editing market in 2025. Asia‑Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mutation detection kits in genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mutation detection kits in genome editing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the mutation detection kits market by increasing costs of imported reagents, sequencing instruments, and bioinformatics software solutions. Segments such as PCR-based kits, CRISPR validation kits, and next-generation sequencing platforms are most affected, with North America and Europe being heavily reliant on imports. This has led to higher operational costs and slowed adoption in academic and biotechnology sectors. On the positive side, tariffs have encouraged local production of reagents and software, spurring innovation and reducing dependency on imports in the long term.

The mutation detection kits in genome editing market research report is one of a series of new reports that provides mutation detection kits in genome editing market statistics, including mutation detection kits in genome editing industry global market size, regional shares, competitors with a mutation detection kits in genome editing market share, detailed mutation detection kits in genome editing market segments, market trends and opportunities, and any further data you may need to thrive in the mutation detection kits in genome editing industry. This mutation detection kits in genome editing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mutation detection kits for genome editing are specialized tools designed to identify and analyze genetic alterations introduced during the editing process. They allow precise detection of insertions, deletions, and substitutions in DNA sequences, ensuring accurate validation of genome editing outcomes. These kits provide essential data for optimizing editing strategies and enhancing experimental efficiency.

The main product types of mutation detection kits in genome editing include reagents, complete kits, and software solutions. Reagents are specialized chemicals or formulations that facilitate specific biochemical reactions in genetic testing, directly impacting the accuracy and reliability of results. These kits employ various genome editing technologies, such as CRISPR, transcription activator-like effector nucleases (TALENs)/MegaTALs, zinc finger nucleases (ZFNs), and other platforms. They are applied across multiple domains, including research, clinical diagnostics, drug development, and related applications, and are used by academic institutions, hospitals, diagnostic laboratories, and biotechnology companies.

The mutation detection kits genome editing market consists of revenues earned by entities by providing services such as the development of specialized assays, manufacturing and distribution of mutation detection kits, CRISPR validation and off-target analysis services, next-generation sequencing (NGS)-based mutation identification, and supplying bioinformatics tools for interpreting genetic modification data. The market value includes the value of related goods sold by the service provider or included within the service offering. The mutation detection kits genome editing market also includes sales of Sanger sequencing-based mutation detection kits, fluorescent reporter-based detection systems, high-resolution melt analysis (HRMA) kits, and droplet digital PCR (ddPCR) mutation detection kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.